Get started
Author

Naoki Cho

Observed name: Cho, Naoki
ORCID: 0000-0003-3544-7008
Observed ORCID: 0000-0003-3544-7008
OpenAlex ID: A5001185966
Association of a reactive intermediate derived from 1′,6‐dihydroxy metabolite with benzbromarone‐induced hepatotoxicity
2017 · Mina Yoshida, Naoki Cho, et al. · Journal of Biochemical and Molecular Toxicology · 15
Identification of novel glutathione adducts of benzbromarone in human liver microsomes
2016 · Naoki Cho, Kaoru Kobayashi, et al. · Drug Metabolism and Pharmacokinetics · 14
ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study
2023 · Natsuki Kubota-Ishida, Chizuko Kaji, et al. · European Journal of Pharmacology · 9
Formation of reactive metabolites of benzbromarone in humanized-liver mice
2022 · Naoki Cho, Hiroshi Suemizu, et al. · Drug Metabolism and Pharmacokinetics · 9
PDF
Safety, Tolerability, and Pharmacokinetics of a Novel Oral Phosphodiesterase 4 Inhibitor, ME3183: First‐in‐Human Phase 1 Study
2023 · Seiji Kato, Naoki Cho, et al. · Clinical Pharmacology in Drug Development · 8
PDF
Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism
2021 · Shogo Matsumoto, Hidetaka Kamimura, et al. · Xenobiotica · 4
Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3115, an Ustekinumab Biosimilar, and EU- and US-Stelara in Healthy Adult Participants: A Randomized, Double-Blind, Single-Dose Study
2025 · Jun Morita, Rainard Fuhr, et al. · Advances in Therapy · 3
PDF
Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets
2022 · Shogo Matsumoto, Shotaro Uehara, et al. · Xenobiotica · 2
Correction: Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study
2026 · Hironori Konishi, Yuji Kumagai, et al. · Advances in Therapy
PDF
Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study
2026 · Hironori Konishi, Yuji Kumagai, et al. · Advances in Therapy
PDF
薬剤性肝障害発症に関与する反応性代謝物の解明手法に関する研究
2023 · 長, 直樹, Cho, Naoki · Institutional Repositories DataBase (IRDB)
PDF
Identification of cytochrome P450 isozymes involved in bioactivation of 1',6-dihydroxy benzbromarone in human liver microsomes
2015 · Naoki Cho · The Japanese Society for the Study of Xenobiotics
Works count: 12
Citation count: 64
H-index: 5
I10-index: 2
Year
Topic
Type